Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 8
Submit an article Journal homepage
67
Views
20
CrossRef citations to date
0
Altmetric
Review

Lactic acidosis related to nucleoside therapy in HIV-infected patients

Vicenç Falcó Infectious Diseases Division. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Pº Vall d’Hebron 119-129 08035 , Barcelona, Spain. [email protected]
,
Manuel Crespo Infectious Diseases Division. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Pº Vall d’Hebron 119-129 08035 , Barcelona, Spain. [email protected]
&
Esteban Ribera Infectious Diseases Division. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Pº Vall d’Hebron 119-129 08035 , Barcelona, Spain. [email protected]
Pages 1321-1329 | Published online: 02 Mar 2005

Bibliography

  • SCHAMBELAN M, BENSON CA, CARR A et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS Society-USA panel. I. Acquic Immune Defic. Syndr: (2002) 31(3):257–275.
  • ••The most recent recommendations on themanagement of metabolic complications, including lactic acidosis, associated with antiretroviral therapy.
  • VROUENRAETS SME, TRESKES M, REGEZ RM et al.: Hyperlactatemia in HIV-infected patients: the role of NRTI-treatment. Antivic Ther. (2002) 7(4):239–244.
  • CARR A, MILLER J, LAW M, COOPER DA: A syndrome of lypoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS (2000) 14(3):F25–F32.
  • •A clinical description of a syndrome of lipoatrophy, lactic acadaemia and liver dysfunction.
  • GERARD Y, MAULIN L, YAZDANPANAH Y et al.: Symptomatic hyperlactataemia: an emergency complication of antiretroviral therapy. AIDS(2000) 14(17):2723–2730.
  • •A prospective and observational study of a cohort of HIViinfected patients that give data on the incidence of symptomatic hyperlactataemia.
  • JOHN M, MOORE CB, JAMES IR et al: Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS(2001) 15(6):717–723.
  • ••This paper gives data about the naturalhistory of hyperlactataemia.
  • SCALZINI A, TOMASONI D, GATTUSO G, FIBBIA G: Prevalence of asymptomatic hyperlactatemia in HIV patients treated with nucleoside analogues. ah International Congress on Drug Therapy in H/Vinfection. Glasgow, UK (2002) MEDI116.
  • HOOKER M, GOODALL RL, CHURCHILL D et al: Incidence of clinical lactic acidosis in patients enrolled in the INITIO trial. ffh International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI111.
  • FALCO V, RODRIGEZ D, RIBERA E et al.: Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin. Infect. Dis. (2002) 34(6):838–846.
  • ••A clinical revision of 12 patients with lacticacidosis. An extensive literature review.
  • TER HOFSTEDE HJM, DE MARIE S, FOUDRAINE NA, DANNER SA, BRINKMAN K: Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int. J. STD AIDS (2000) 11(9):611–616.
  • BOUBAKER K, FLEPP M, SUDRE P et al.: Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin. Infect. Dis. (2001) 33(11):1931–1937.
  • •An estimation of the prevalence of hyperlactataemia in a large observational cohort of HIV-infected patients receiving antiretroviral therapy.
  • MANFREDI R, MOTTA R, PATRONO D, CALZA L, CHIODO F, BONI P: Elevated lactacidaemia during HIV disease: preliminary data from a prospective case-control study evaluating the frequency, possible risk factors, and clinical significance. 6h International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI123.
  • LONERGAN JT, BEHLING C, PFANDER H, HASSANEIN TI, MATHEWS WC: Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin. Infect. Dis. (2000) 31(1):162–166.
  • MOYLE GJ, DATTA D, MANDALIA S, MORLESE J, ASBOE D, GAZZARD BJ: Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS (2002) 16(10):1341–1349.
  • •A cross-sectional, longitudinal study to evaluate the prevalence, outcome and possible risk factors for hyperlactataemia and lactic acidosis. It concludes that screening of lactate is of limited use in asymptomatic patients on antiretroviral therapy.
  • KAKUDA TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Titer. (2000) 22(6): 685–708.
  • ••This paper reviews the function of themitochondria and the mechanisms of toxicity of nucleoside analogues.
  • BARTLE M, VALENTI D, QUAGLIARELLO E, PASSARELLA S: Mitochondria as cell targets of AZT (Zidovudine). Gen. Pharm. (1998) 31(4):531–538.
  • •A review of the mechanisms of mitochondrial toxicity caused by zidovudine.
  • GARCIA DE LA ASUNCION J, DEL OLMO ML, SASTRE J, PALLARDO FV, VIIJA J: Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology (1999) 29(3):985–987.
  • GARCIA DE LA ASUNCION J, DEL OLMO ML, SASTRE J et al.: AZT induces molecular and ultra structural oxidative damage to muscle mitochondria: prevention by antioxidant vitamins. Clin. Invest. (1998) 102(1):4–9.
  • MCCALLISTER SM, ALONSO MC: Clinical, virologic and immunologic significance of lactic acid levels in HIV positive adults. 46h Interscience Conference on Antimicrob. Agents Chemother: Toronto, Canada (2000) MEDI1301.
  • GREENBERG RN, RAPP D, THORNTON AC: Elevations of plasma lactic acid in HIV patients receiving nucleoside reverse transcriptase inhibitors. Interscience Conference on Antimicrob. Agents Chemothec Toronto, Canada (2000) MEDI1300.
  • MOYLE G: Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible aetiologies. AIDS Rev (2001) 3:150–156.
  • •A review of the causes and management of hyperlactataemia and lactic acidosis.
  • COGLAN ME, SOMMADOSSI JP, JHALA NC, MANY WJ, SAAG MS, JOHNSON VA: Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin. Infect. Dis. (2001) 33(11):1914–1921.
  • •A clinical and histopathological description of 12 cases of lactic acidosis in HIV-infected patients.
  • FREIMAN JP, HELFERT KE, HAMRELL MR, STEIN DS: Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS (1993) 7(3):379–385.
  • BISSUEL F, BRUNEEL F, HABERSETZER F et al.: Fulminant hepatitis with severe lactic acidosis in HIV-infected patients on didanosine therapy. .1 Intern. Med. (1994) 235(4):367–371.
  • OLANO JP, BORUCKI MJ, WEN JW, HAQUE AK: Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin. Infect. Dis. (1995) 21(4):973–976.
  • FORTGANG IS, BELITSOS PC, CHAISSON RE, MOORE RD: Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am. Castroenterol (1995) 90(9):1433–1436.
  • LENZO NP, GARAS BA, FRENCH MA: Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS (1997) 11(10):1294–1296.
  • SUNDAR K, SUAREZ M, BANOGON PE, SHAPIRO J: Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit. Care Med. (1997) 25(8):1425–1430.
  • CHARIOT P, DROGOU I, DE LACROIX-SZMANIA I et al.: Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. Hepatol (1999) 30(1):156–160.
  • BRIVET FG, NION I, MEGARBENE B et al.: Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? .1. Hepatol (2000) 32(2):365–365.
  • CLARK SJ, CREIGHTON S, PORTMANN B, TAYLOR C, WEND ON JA, CRAMP E: Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. .1. Hepatol (2002) 36(2):295–301.
  • ELLOY S, MASSEN R, CHAO L, DIVINO CM: Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature. Am. Surg. (2001) 67(7):680–683.
  • VERMA A, SCHEIN RMH, JAYAWEERA DT, KETT DH: Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy. Neurology (1999) 53(6):1365–1367.
  • SIMPSON D, ESTANISLAO L, MARCUS K et al: HIV-associated neuromuscular weakness syndrome. la-h Conference on Retro viruses and Opportunistic Infections. Boston, USA (2003) MEDI87.
  • ALLAOUCHICHE B, DUFLO F, COTTE L, MATHON L, CHASSARD D: Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy.' Antimicrob. Chemother: (1999) 44(1):137–138.
  • ARENAS A, GRANT AD, EDWARDS S, WELLER IVD: Lactic acidosis in HIV-infected patients: a systematic review of published cases. ah International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI121.
  • MOKRZYCKI MH, HARRIS C, MAY H, LAUT J, PALMISANO J: Lactic acidosis associated with stavudine administration: a report of five cases. Clin. Infect. Dis. (2000) 30(1):198–200.
  • BLANCO F, GARCIA-BENAYAS T, DE LA CRUZ JJ, GONZALEZ-LAHOZ J, SORIANO V: First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials (2003) 4(1):11–19.
  • CIHLAR T, CHEN MS: Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases a, 13 and y. Antiviral Chem. Chemoter (1997) 8(3):187–195.
  • ••Study that demonstrates the ability ofcellular DNA polymerases to recognise nucleotide analogues as their substrates and incorporate them into DNA.
  • LAI KK, GANG DL, ZAWACKI JK, COOLEY TP: Fulminant hepatic failure associated with 2', 3'-dideoxyinosine (ddI). Ann. Intern. Med. (1991) 115(4):2834.
  • CHATTHA G, ARIEFF Al, CUMMINGS C, THIERNEY LM Jr: Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann. Intern. Med. (1993) 118(1):37–39
  • COYLE T, ABEL E: Lactic acidosis and AIDS. Ann. Intern. Med. (1993) 119(4)344.
  • CHARIOT P, DUBREUIL-LEMAIRE ML, GHERARDI R: Lactic acidosis and AIDS. Ann. Intern. Med. (1993) 119(4):344–345.
  • BARAM D, COOKE J: Lactic acidosis and AIDS. Ann. Intern. Med. (1993) 119(4):345.
  • MASLO C, JACOMET C, JUPAS JJ, LEBRETTE MG, ROZENBAUM W: Lactic acidosis in HIV-infected patients. Presse Med. (1994) 23(15):717.
  • AGGARWAL A, AL-TALIB K, ALABRASH M: Type B lactic acidosis in an AIDS patient treated with zidovudine. Md Med. (1996) 45(11):929–931.
  • MOULY S, KHUONG MA, CABIE A, SAIMOT AG, COULAD JP: Ben-ben i and thiamine deficiency in HIV infection. AIDS (1996) 10(8):931–932.
  • CHARTON-BAIN MC, FLAMANT M, AUBERTIN JM et al.: Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine. Castroenterol Clin. Biol. (1997) 21(12):979–981.
  • ROY PM, GOUELLO JP, PENNISON-BESNIERE I, CHENNEBAULT JM: Severe lactic acidosis induced by nucleoside analogues in an HIV-infected man. Ann. Emerg. Med. (1999) 34(2):282–284.
  • ACOSTA BS, GRIMSLEY EW: Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South. Med.' (1999) 92(4):421–423.
  • LAFEUILLADE A, HITTINGER G, CHADAPAUD S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet (2001) 357(9252):280–281.
  • CHODOCK R, MYLONAKIS E, SHEMIN D et al.: Survival of a Human Antimicrob. Agents Chemother. (1992) 36(8):1688–1694. MARTIN JL, BROWN CE, MATTHEWS-DAVIS N, REARDON JE: Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. (1994) 38(12):2743–2749. BIRKUS G, HITCHCOCK MJM, CIHLAR T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (2002) 46(3):716–723. Immunodeficiency patient with nucleoside induced lactic acidosis-role of a haemodialysis treatment. Nephrol. Transplant. (1999) 14(10):2484–2486.
  • BRINKMAN K: Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue transcriptase inhibitors. Clin. Infect. Dis. (2000) 31(1):167–169.
  • DELGADO J, HARRIS M, TESIOROWSKI A, MONTANERJSG: Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin. Infect. Dis. (2001) 33(12):2072–2074.
  • LOPEZ S, MIRO 0, GARCIA M et al.: Reversible mitochondrial DNA depletion and mitochondrial respiratory chain dysfunction in symptomatic hyperlactatemia. h International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI119.
  • BRINKMAN K, TER HOFSTEDE HJM: Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev (1999) 1:140–146.
  • •In this review, risk factors for mitochondrial toxicity and therapeutic options of lactic acidosis are analysed.
  • VENHOFF N, SETZER B, LEBRECHT D, WALKER UA. Dietary supplements in the treatment of nucleoside reverse transcriptase inhibitor-related mitochondrial toxicity. AIDS (2002) 16:800–802.
  • FOUTY B, FRERMAN F, REVES R. Riboflavin to treat nucleoside analogue induced lactic acidosis. Lancet (1998) 352(9124):291–292.
  • LUZZATI R, DEL BROVE P, DI PERRI G, LUZZANI A, CONCIA E: Riboflavin and severe lactic acidosis. Lancet (1999) 353(9156):901–902.
  • SCHRAMM C, WANITSCHKE R, GALLE PR: Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur. Anesthesia (1999) 16(10):733–735.
  • CLAESSENS YE, CARIOU A, CHICHE JD, DAURIAT G, DHAINAUT JF: L-carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS (2000) 14(4):472–473.
  • POSTERARO AF 3rd, MAURIELLO M, WINTER SM: Riboflavin treatment of
  • ARICI C, TEBALDI A, QINZAN GP, MAGGIOLO F, RIPAMONTI D, SUTER F: Severe lactic acidosis and (2001) 12(6):407–409.
  • IGOUDJIL A, MAISONNEUVE C, NOTE R et al: L-carnitine prevents mitochondrial toxicity and metabolic
  • BRINKMAN K, KAKUDA TN: Mitochondrial toxicity of nucleoside antiretroviral therapy? Curt: Opin. Infect. Dis. (2000) 13(1):5–11.
  • BRINKMAN K, TER HOFSTEDE HJM, BURGER DM, SMEITINK JA, KOOPMANS PP: Adverse effects of reverse
  • KHOURI S, CUSHING H: Lactic acidosis.
  • GEY D, BOIT R, LORENZ T et al: Safety, tolerability and efficacy of an NRTI- free mitochondrial toxicity: a pilot study. 6th International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI122.
  • HART CG, ORR DC, PENN CR et al: Effects of ( ) 2' deoxy 3' thiacytidine (lamivudine) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.
  • BRINKMAN K: Management of hyperlactatemia: no need for routine lactate measurements. AIDS (2001) 15(6):795–797.
  • COTE. HCF, BRUMME ZL, KEVIN BS et al.: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl. Med. (2002) 346(11):811–820.
  • MILLER KD, CAMERON M, WOOD LV, DALAKAS MC, KOVACS JA: Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann. Intern. Med. (2000) 133(3):192–196.
  • GARCIA-BENAYAS T, BLANCO F, SORIANO V, GONZALEZ J: Switching stavudine by abacavir lowers lactate levels. Gh International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI114.
  • HARRIS M, COTE HCF, CHAN JW et al.: Replacing stavudine (d4T) with tenofovir DF (TDF) maintains antiviral effect and reduces mitochondrial toxicity. 6th International Congress on Drug Therapy in HIV infection. Glasgow, UK (2002) MEDI118.
  • BARTHELEMY C et al: Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?' Acquic Immune Defic. Syndr. (2002) 31(3):299–308.
  • BARTHELEMY C et al: Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?' Acquic Immune Defic. Syndr. (2002) 31(3):299–308.
  • MCCOMSEY G, TAN DJ, LEDERMAN M, WILSON E, WONG LJ: Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS (2002) 16(4):513–518.
  • VITTECOQ D, JARDEL C, BARTHELEMY C et al: Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder?' Acquic Immune Defic. Syndr. (2002) 31(3):299–308.

Websites

  • http.//www.fda.govibbs/topics/answers/ans01 063 htlm. US FDA, FDA/BRISTOL-MYERS SQUIBB: Issues caution for HIV combination therapy with Zerit and Videx in pregnant women. FDA Talk Paper (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.